Insights

  • Date

  • Content Type

  • Reset

Blog

The art of giving advice – why and how great consultants make a real difference!

20.08.20

By Timo Liebig

Drug development is an extremely complex endeavor and a plethora of interdisciplinary skills is required to successfully develop...

Blog

How far are we with the accelerated development of SARS-CoV-2 vaccines – a review and outlook

13.08.20

By Noemi Lupo and Michael Pfleiderer

Development of SARS-CoV-2 vaccine comes with an unprecedented number of challenges ranging from CMC to clinical development. This...

Blog

Navigating the maze of environmental risk assessments for genetically modified products including ATMPs/CGTs

5.08.20

By Jörg Schneider


Environmental risk assessments (ERAs) for medicines containing genetically modified products are a prerequisite for clinical trial applications and...

Blog

Essential safety considerations for cell and gene therapies

3.07.20

By David Koziel

Cell and gene therapies offer novel approaches for many still unmet medical needs, like severe inherited and acquired...

Blog

Unravelling the regulatory riddle for exosome-based therapies

16.06.20

By Nermina Vejzagic

Exosomes are nanosized extracellular vesicles emerging as a new therapeutic platform.Development and regulation of exosome pose a challenge...

Blog

Key features of the Voluntary Harmonisation Procedure (VHP)

7.06.20

By Liron Sarid-Krebs

The VHP allows simultaneous initiation of the clinical trial authorisation procedure in several European countries with a...

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more